H.R. 482 117th Congress
Newborn Screening Saves Lives Reauthorization Act of 2021
- Health
- Sponsor: Rep. Roybal-Allard, Lucille [D-CA-40]
- Congress.gov ↗
Latest action, Jun 24, 2021: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
57 cosponsors
Sponsored by Rep. Roybal-Allard, Lucille [D-CA-40] (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
43 D · 14 R
- Democrat
- Republican
- Independent
Referred to: Senate: Health, Education, Labor, and Pensions Committee; House: Energy and Commerce Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
AMERICAN COLLEGE OF MEDICAL GENETICS
KING & SPALDING LLP
8 reports
8 reports
8 reports
8 reports
TRAVERE THERAPEUTICS
ALSTON & BIRD LLP
8 reports
8 reports
BIOMARIN PHARMACEUTICAL INC.
CHAMBER HILL STRATEGIES
7 reports
NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS
MASON CONSULTING, LLC
7 reports
RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)
7 reports
6 reports
6 reports
CAE USA INC.
5 reports
CAE USA, INC
ALPINE GROUP PARTNERS, LLC.
5 reports
COALITION TO PRESERVE INDEPENDENT CONTRACTOR STATUS
HOLLRAH LLC
5 reports
All 25 of 34 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMERICAN COLLEGE OF MEDICAL GENETICS | KING & SPALDING LLP | 8 | $160K | Q1 2021 | Q3 2022 | yes |
| MARCH OF DIMES | 8 | $550K | Q1 2021 | Q3 2022 | yes | |
| MUSCULAR DYSTROPHY ASSOCIATION, INC. | 8 | $1.1M | Q1 2021 | Q3 2022 | yes | |
| TAKEDA PHARMACEUTICALS AMERICA INC | 8 | $9.4M | Q1 2021 | Q3 2022 | yes | |
| TRAVERE THERAPEUTICS | ALSTON & BIRD LLP | 8 | $0 | Q1 2021 | Q3 2022 | yes |
| TRAVERE THERAPEUTICS | 8 | $1.3M | Q1 2021 | Q3 2022 | yes | |
| BIOMARIN PHARMACEUTICAL INC. | CHAMBER HILL STRATEGIES | 7 | $0 | Q4 2021 | Q3 2022 | yes |
| NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS | MASON CONSULTING, LLC | 7 | $168K | Q4 2021 | Q3 2022 | yes |
| RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES) | 7 | $140K | Q4 2021 | Q3 2022 | yes | |
| AMERICAN ACADEMY OF PEDIATRICS | 6 | $1.4M | Q4 2021 | Q3 2022 | yes | |
| AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS | 6 | $806K | Q4 2021 | Q2 2022 | yes | |
| CYSTIC FIBROSIS FOUNDATION | 6 | $630K | Q1 2021 | Q3 2022 | yes | |
| CAE USA INC. | 5 | $620K | Q4 2021 | Q3 2022 | yes | |
| CAE USA, INC | ALPINE GROUP PARTNERS, LLC. | 5 | $300K | Q4 2021 | Q3 2022 | yes |
| COALITION TO PRESERVE INDEPENDENT CONTRACTOR STATUS | HOLLRAH LLC | 5 | $0 | Q4 2021 | Q3 2022 | yes |
| MYSTERY SHOPPING PROVIDERS ASSOCIATION, INC. | HOLLRAH LLC | 5 | $0 | Q4 2021 | Q3 2022 | yes |
| PRIVATE CARE ASSOCIATION INC | HOLLRAH LLC | 5 | $50K | Q4 2021 | Q3 2022 | yes |
| AMERICAN SOCIETY OF HEMATOLOGY | 4 | $120K | Q1 2022 | Q3 2022 | yes | |
| BIOMARIN PHARMACEUTICAL INC. | 4 | $970K | Q2 2021 | Q3 2022 | yes | |
| AEGLEA BIOTHERAPEUTICS, INC. | THE KPM GROUP DC LLC | 3 | $90K | Q1 2021 | Q3 2021 | yes |
| RARE DISEASE COMPANY COALITION | THE KPM GROUP DC LLC | 3 | $90K | Q4 2021 | Q3 2021 | yes |
| THE MENDED HEARTS, INC. | CURA STRATEGIES | 3 | $47K | Q4 2022 | Q3 2022 | yes |
| ULTRAGENYX PHARMACEUTICAL | THE KPM GROUP DC LLC | 3 | $145K | Q1 2021 | Q3 2021 | yes |
| ALEXION PHARMACEUTICALS, INC. | 2 | $430K | Q2 2021 | Q3 2021 | yes | |
| AMERICAN CIVIL LIBERTIES UNION | 2 | $980K | Q1 2021 | Q2 2021 | yes |